Integral Diagnostics Ltd (ASX:IDX)

Half Year 2025 Integral Diagnostics Ltd Earnings Call Transcript

Feb 25, 2025 / 12:00 AM GMT

Release Date Price: A$2.51 (-12.24%)

Transcript

Key Points

Positve

Integral Diagnostics Ltd (ASX:IDX) reported solid revenue growth of 7.8% and operating EBITDA growth of 8.2% for the first half of FY25.
The company successfully completed its merger with Capital Health, which is expected to deliver at least $10 million in synergies, with most benefits realized in the first year.
IDX has demonstrated strong patient satisfaction, with net promoter scores of 83 in Australia and 79 in New Zealand.
The company is well-positioned to benefit from regulatory changes, including MRI deregulation and the national lung cancer screening program, which are expected to drive future growth.
IDX has increased its free cash flow by 22.7% and improved its operating diluted earnings per share by 14.2%.

Negative

IDX faced challenges with clinical staff shortages and labor cost inflation, particularly in regional areas, impacting margins.
The company was adversely affected by a 2% reduction in Medicare reimbursement for CT services, as it is overindexed in CT revenue.
IDX's operating margin was constrained by higher clinical labor costs, despite efforts to contain non-clinical labor expenses.
The company experienced a $1 million operating impact loss from Capital Health during the Christmas-New Year period due to high fixed costs and low revenue.
IDX's growth in Australia was below Medicare growth rates, partly due to capped contracts in regional areas that limited revenue recognition.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IDX.AX - Integral Diagnostics Ltd
Half Year 2025 Integral Diagnostics Ltd Earnings Call
Feb 26, 2025 / 12:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to the Integral Diagnostics IDX FY25 half year results. All participants are in a listen-only mode. There will be a presentation followed by a question and answer session. If you wish to ask a question, you will need to press the star key followed by the number one on your telephone keypad.

I would now like to hand the conference over to Doctor Ian Kadish, CEO. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you very much, Drew.

Good morning, everyone. My name is Ian Kadish. I'm the chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.